• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Astellas Pharma Inc (OP: ALPMY )

    11.75 +0.35 (+3.07%)
    Streaming Delayed Price Updated: 10:31 AM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Astellas Pharma Inc

    < Previous 1 2 3 Next >
    1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
    It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
    Via The Motley Fool
    Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
    William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
    Via Benzinga
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
    Via Investor's Business Daily
    Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
    Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
    Via Benzinga
    MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
    MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
    Via Talk Markets
    Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
    Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
    Via Talk Markets
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
    Via Benzinga
    How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
    The companies studied a combination of Keytruda and Padcev in bladder cancer patients. 
    Via Investor's Business Daily
    Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
    Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
    Via Benzinga
    Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
    The multibillionaire's portfolio features some moneymaking ideas. 
    Via The Motley Fool
    Why Is Seagen Stock Trading Higher Today?
    Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
    Via Benzinga
    Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
    The companies tested a key combination in patients with previously untreated bladder cancer. 
    Via Investor's Business Daily
    What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
    Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected  
    Via Benzinga
    How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
    Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
    The company is already under scrutiny after reports of side effects tied to Syfovre. 
    Via Investor's Business Daily
    From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
    Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
    Via Benzinga
    Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
    Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates... 
    Via Talk Markets
    Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
    Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as  
    Via Benzinga
    The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
    Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
    Via Investor's Business Daily
    Why Shares of Annexon Are Plummeting Thursday
    Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
    Via The Motley Fool
    Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
    Bloomberg 
    Via Benzinga
    Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
    The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes 
    Via Benzinga
    Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
    These three biotech stocks were on the volatile side today. 
    Via The Motley Fool
    Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
    Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced  
    Via Benzinga
    Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
    The company is working on a treatment for the eye disease known as geographic atrophy. 
    Via Investor's Business Daily
    First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
    Benzinga 
    Via Benzinga
    Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
    Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. 
    Via Benzinga
    Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
    Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
    Via Benzinga
    FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
    Via Benzinga
    Japanese Government Urges China To Release Astellas Pharma's Employee
    The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities.  The reasons why the person was... 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.